22 results about "Treatment refractory" patented technology

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

This invention relates to a crystalline form of camlipixant and its use in pharmaceutical compositions as well as in therapy, in particular use in the treatment of refractory chronic cough. (I)

The invention provides compositions and methods for treating a refractory, relapsed or resistant cancer or a chronic infectious disease. In particular the present invention relates to a modified immune cell with reduced SUV39H1 activity, for use in the treatment of a patient suffering from a refractory, relapsed or resistant cancer or suffering from a chronic infectious disease, wherein the cell expresses one or more engineered antigen-specific receptors that bind an antigen associated with the cancer or the chronic infectious disease

Provided herein are compounds, including ifenprodil, and pharmaceutical compositions for use in treating refractory chronic cough. The compounds and pharmaceutical compositions may also be suitable for treating refractory chronic cough in subjects also diagnosed with idiopathic pulmonary fibrosis.

The present application discloses a composition for the treatment of painful disc damage syndrome (PDDS), disc bulging, disc herniation, and disc protrusion, as well as an administration method and a recommended treatment protocol for administering an effective dose of the composition to a patient. The composition has anti-inflammatory, antioxidant, vasodilatory, and antispasmodic properties. The compound is administered intravenously over a specific period for pain relief.

The invention belongs to the technical field of biological medicine, and relates to application of ABT-737 in preparation of anti-inflammatory drugs, in particular to application of ABT-737 in preparation of drugs for treating refractory rheumatoid arthritis. It is found for the first time that ABT-737 can induce apoptosis of inflammatory T cells derived from peripheral blood or synovial fluid of a patient suffering from the refractory rheumatoid arthritis, reduce the number of the inflammatory T cells and further inhibit occurrence and development of inflammation, and therefore ABT-737 has the prospect of being developed into drugs for treating the refractory rheumatoid arthritis and anti-inflammatory or immunomodulatory drugs.

The invention discloses a traditional Chinese medicine composition for treating refractory helicobacter pylori infection and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 15-20 parts of codonopsis pilosula, 10-15 parts of roasted rhizoma atractylodis macrocephalae, 15-20 parts of oldenlandia diffusa, 6-9 parts of coptis chinensis, 6-9 parts of rhizoma pinellinae praeparata, 6-9 parts of curcuma zedoary and 6-9 parts of raw liquorice. The invention also provides a preparation method and a traditional Chinese medicine preparation of the traditional Chinese medicine composition. The traditional Chinese medicine composition and the traditional Chinese medicine preparation thereof are simple in prescription, can be used for effectively treating intractable helicobacter pylori infection, and are beneficial to relieving the medicine taking and economic burden of patients, improving the compliance and reducing the occurrence of adverse reactions.

An antibody-drug conjugate containing a side chain of a functional small molecule for enhancement of targeted treatment of cancers and refractory diseases is provided. The preparation of such conjugate, pharmaceutical compositions, and methods in treatment of refractory diseases are also provided.

The present invention relates to a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and / or relapsed cancer. The invention also relates to a method of treating refractory cancer and / or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and / or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.

To provide effective therapeutic agents for the treatment of refractory lymphatic and vascular diseases. Provided is a therapeutic agent for the treatment of refractory lymphatic and vascular diseases which contains sirolimus as an active ingredient. The administration of the therapeutic agent is initiated by oral or tube administration at a dosage determined according to parameters related to the pharmacokinetics of sirolimus in a patient having the disease and the weight and age of the patient.

To provide an effective, long-term and safe pharmaceutical composition for use in a method of treating treatment-refractory or treatment-resistant depression in a patient diagnosed as having the depression.SOLUTION: A pharmaceutical composition for use in a method of treating treatment-resistant depression in a patient, wherein the pharmaceutical composition comprises esketamine and wherein the patient has not responded to at least two oral antidepressants in a current depressive episode, the pharmaceutical composition comprising: The method provides a pharmaceutical composition comprising: administering esketamine to the patient at least twice a week during a first induction phase of at least 4 weeks; evaluating the patient during the first induction phase; wherein the patient does not achieve a substantially complete response to esketamine; and re-starting the patient with the highest tolerated dose of esketamine in a second induction phase of at least 4 weeks.SELECTED DRAWING: None

Disclosed herein are methods of treating or reducing incidence of migraine and / or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present application discloses a composition for treating painful disc injury syndrome (PDDS), disc bulging, disc herniation, and disc herniation, as well as a delivery method and recommended treatment regimen for delivering an effective dose of the composition to a patient. The composition has the characteristics of inflammation resistance, oxidation resistance, vasodilation and spasmolysis. The composition is administered by intravenous drip over a specific period of time to relieve pain.

IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25+ and / or CCR4+ cutaneous T cell lymphoma, and other human CD25+ or CCR4+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25+ or CCR4+ Tregs.

Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and / or relapsed cancer, and of a method of treating refractory cancer and / or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

The present invention relates to a composition for determining subtypes of triple-negative breast cancer and a composition for preventing or treating triple-negative breast cancer. By measuring the expression level of DNp63α, which is a biomarker identified in the present invention, the molecular subtypes of triple-negative breast cancer can be accurately classified. Based on the classified molecular subtypes, the therapeutic responsiveness to specific therapeutic agents is predicted with high reliability, thereby significantly contributing to early establishment of treatment strategies and improved patient survival. In addition, the composition of the present invention significantly induces apoptosis of cancer cells by inhibiting the expression of DNp63α in triple-negative breast cancer expressing DNp63α, and thus can be effectively used as an efficient therapeutic composition for triple-negative breast cancer, which is refractory solid cancer.

To provide methods for administering chimeric antigen receptor (CAR)-T cells for treatment of human patients susceptible to or diagnosed with a disease, such as cancer.SOLUTION: A method of treating a subject who has refractory and / or relapsed non-Hodgkin's lymphoma comprises administering to the subject at least one dose of allogeneic chimeric antigen receptor (CAR)-T cells (CAR-T cells) comprising an anti-human CD19 4-1BB / CD3zeta CAR, where the at least one dose is about 20×106 cells / dose to about 360×106 cells / dose.SELECTED DRAWING: Figure 4A

Provided is a use of the prophylaxis, amelioration or therapy of intractable epilepsy, for example, Focal Cortical Dysplasia (FCD).

The present invention discloses a kit for non-invasive diagnosis of type 2 chronic rhinosinusitis with nasal polyps. One technical solution protected by the present invention is the application of a system for detecting the content of inflammatory factors in the preparation of a product for diagnosing or assisting in diagnosing whether a patient with chronic rhinosinusitis with nasal polyps is a patient with type 2 chronic rhinosinusitis with nasal polyps. The inflammatory factors may be interleukin-5, CC chemokine ligand 5 and CC chemokine ligand 26, or interleukin-5, CC chemokine ligand 5, CC chemokine ligand 24, CC chemokine ligand 26 and periostin. The diagnostic AUC of the kit and device for non-invasive rapid diagnosis of type 2 CRSwNP before treatment provided by the present invention is 0.862 or 0.856, both of which are higher than the current clinical indicators for diagnosing type 2 CRSwNP, and can provide a basis for selecting the correct treatment plan, reasonable drugs, biological agents or surgical methods for treating refractory CRSwNP clinically.

The present invention relates to methods for treating patients with refractory chronic cough (RCC) with nalbuphine compositions, wherein the method provides a therapeutic effect in a patient.